← Back to all trials
Recruiting
NCT07205666
The Eplontersen Pregnancy and Lactation Outcomes Study
Conditions: Transthyretin Amyloidosis
Sex: All
Healthy volunteers: No
Enrollment: 10
Sponsor: AstraZeneca
Location: Research Site Frankfurt
Summary
The overall objective of this DPSS is to describe the occurrence of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant associated with exposure to eplontersen during pregnancy and/or lactation.
Eligibility Criteria
Inclusion Criteria:
* all pregnancy and/or lactation cases with exposure to eplontersen and a diagnosis of an approved indication for treatment with eplontersen
* all adverse event reports in infants in the first 12 months of age that are or can be linked to pregnancy or lactation reports in individuals previously diagnosed with an approved indication and exposed to eplontersen during pregnancy or lactaction
Exclusion Criteria:
* all case reports considered invalid (i.e. minimum data is not provided at first report nor follow-up), or where reporter indicates that they do not wish to be contacted to obtain follow-up information, or the reporter/patient cannot be identified
Source: ClinicalTrials.gov (NCT07205666). StuddyBuddy aggregates publicly available trial information.